

• **Name:** Tae Kon Kim

• **Affiliation/Current Position:** Assistant Professor of Medicine

• **Country:** USA

• **ICKSH2022 Presentation Title:** Adaptive immune resistance and immune evasion by PD-1H/VISTA in acute myeloid leukemia

• **Educational Background:**

Ph.D. Univ. of Texas, MD Anderson Cancer Center (Immunology/Biomedical Sciences) 2010

M.D. Seoul National University College of Medicine 2001

• **Professional Experiences:**

03/01-02/02 Intern, Internal Medicine, Seoul National University Hospital, Seoul, S. Korea

11/02-07/05 Visiting scholar in Hematology, University of Pennsylvania, Philadelphia, PA

08/05-06/10 Graduate Research Associate, Univ. of Texas, MD Anderson Cancer Center, TX

06/10-06/13 Resident, Internal Medicine, Univ. of Miami/Jackson Memorial Hospital, Miami, FL

07/13-06/16 Fellow, Program in Hematology/Oncology, Yale-New Haven Hospital, New Haven, CT

07/16-06/19 Clinical Instructor, Section of Hematology, Yale School of Medicine, New Haven, CT

07/19-present Assistant Professor, Division of Hematology/Oncology, Dept of Medicine, Dept of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN

07/19-present Adjunct Assistant Professor, Section of Medical Oncology, Yale School of Medicine, New Haven, CT

• **Professional Organizations:** ASH, AACR, ASTCT

• **Main Scientific Publications:**

1. Han X, Vesely MD, Yang W, Sanmamed MF, Badri T, Alawa J, Lopez-Giraldez F, Gaule P, Lee SW, Zhang JP, Nie X, Nassar A, Boto A, Fliess DB, Zheng L, **Kim TK**, Moeckel GW, McNiff JM, Chen L. PD-1H (VISTA)-mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus. *Sci Transl Med*. 2019 Dec 11
2. **Kim TK**, DeVaux M, Stahl M, Perreault S, Isufi I, Cooper D, Foss F, Shlomchik WD, Zelterman D, Zeidan AM, Seropian S. Letter to the Editor: Long Term Follow Up of a Single Institution Pilot Study of Sirolimus, Tacrolimus, and Short Course Methotrexate for Graft

- Versus Host Disease Prophylaxis in Mismatched Unrelated Donor Allogeneic Stem Cell Transplantation. *Ann Hematol.* 2019 Jan
3. **Kim TK**, Herbst RS, Chen L. Defining and understanding adaptive resistance in cancer immunotherapy. *Trends Immunol.* 2018 May 22
 4. Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard J, Podoltsev NA, Brunner A, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, **Kim TK**, Prebet T, Vey N, Verma V, Germing U, Bergua J, Serrano J, Gore SD, Zeidan AM. Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed and refractory acute myeloid leukemia. *Leuk Lymphoma* 2019 Jan
 5. Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard J, Podoltsev NA, Brunner A, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, **Kim TK**, Prebet T, Vey N, Verma V, Germing U, Bergua J, Serrano J, Gore SD, Zeidan AM. Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. *Blood Adv.* 2018; 2(8):923-932
 6. Stahl M, Pine A, Hendrickson JE, Litzow MR, Luger SM, Stone RM, Erba HP, **Kim TK**, Sekeres MA, Steensma DP, Komrokji RS, Gore SD, Zeidan AM. Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large US web-based survey. *Leuk Lymphoma* 2018
 7. Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard J, Podoltsev NA, Brunner A, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, **Kim TK**, Prebet T, Vey N, Verma V, Germing U, Bergua J, Serrano J, Gore SD, Zeidan AM. Allogeneic hematopoietic stem cell transplantation following the use of hypomethylating agents among patients with relapsed and refractory AML: Findings from an international retrospective study. *Biol Blood Marrow Transplant.* 2018
 8. Li AW, Yin ES, Stahl M, **Kim TK**, Panse G, Zeidan AM, Leventhal JS. The skin as a window to the blood: Cutaneous manifestations of myeloid malignancies. *Blood Rev.* 2017 Nov;31(6):370-388
 9. Stahl M, Lu BY, **Kim TK**, Zeidan AM. Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock? *Target Oncol.* 2017 Aug; 12(4): 413-447
 10. Stahl M, **Kim TK**, Zeidan AM. Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities. *World J Stem Cells.* 2016 Oct 26;8(10):316-331.
 11. Stahl M, Kohrman N, Gore SD, **Kim TK**, Zeidan AM, Prebet T. Epigenetics in Cancer: A Hematological Perspective. *PLoS Genet.* 2016 Oct 10;12(10):e1006193.
 12. **Kim TK**, Xu ML, Podoltsev NA, Prebet T, Barbarotta L, Amin K, Kasberg S, Roche K, Stahl M, Gore SD, Zeidan AM. Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia. *Ann Hematol.* 2016 Jul 29.
 13. **Kim TK**, Gore SD, Zeidan AM. Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions. *Semin Hematol.* 2015 Jul;52(3):172-83
 14. LaConti JJ, **Kim TK**, Whittington E, Ding N, Dinh V, Moh'd K, Umar S, Glück S. Metastatic Seminoma Presenting as Enlarging Retroperitoneal Mass in a Patient with Neurofibromatosis I. *J Clin Case Rep.* 2014 June 30;4:380
 15. Shindo T, **Kim TK**, Benjamin CL, Levy RE, Wieder ED, Komanduri KV. MEK inhibitors selectively suppress alloreactivity and graft-versus-host disease in a memory stage-dependent manner. **(co-first author, Plenary paper)** *Blood.* 2013 Jun 6;121(23):4617-26.
 16. Joseph RW, Bayraktar UD, **Kim TK**, John LS, Popat U, Khalili J, Mollidrem JJ, Wieder ED, Komanduri KV. Vitamin D receptor upregulation in alloreactive human T cells. *Hum Immunol.* 2012 Apr 28.
 17. Bayraktar UD, **Kim TK**, Drews-Elger K, Benjamin C, El-Ashry D, Wieder ED, Komanduri KV. Simultaneous measurement of ER α , HER2, and PhosphoERK1/2 in breast cancer cell lines by flow cytometry. *Breast Cancer Res Treat.* 2011 May 24.
 18. Li D, Li Y, Hernandez JA, Patenia R, **Kim TK**, Khalili J, Dougherty MC, Hanley PJ, Bollard CM, Komanduri KV, Hwu P, Champlin RE, Radvanyi LG, Mollidrem JJ, Ma Q. Lovastatin inhibits T-cell proliferation while preserving the cytolytic function of EBV, CMV, and MART-1-specific CTLs. *J Immunother.* 2010 Nov-Dec;33(9):975-82.
 19. Carreño R, Brown WS, Li D, Hernandez JA, Wang Y, **Kim TK**, Craft JW Jr, Komanduri KV, Radvanyi LG, Hwu P, Mollidrem JJ, Legge GB, McIntyre BW, Ma Q. 2E8 binds to the high

- affinity I-domain in a metal ion-dependent manner: a second-generation monoclonal antibody selectively targeting activated LFA-1. *J Biol Chem*. 2010 Oct 22 ;285(43):32860-8.
20. **Kim TK**, Billard MJ, Wieder ED, McIntyre BW, Komanduri KV. Coengagement of $\alpha 4 \beta 1$ integrin (VLA-4) and CD4 or CD8 is necessary to induce maximal Erk1/2 phosphorylation and cytokine production in human T cells. *Hum Immunol*. 2010 Jan;71(1):23-8.
 21. **Kim TK**, St John LS, Wieder ED, Khalili J, Ma Q, Komanduri KV. Human late memory CD8+ T cells have a distinct cytokine signature characterized by CC-chemokine production without IL-2 production. *J Immunol*. 2009 Nov 15;183(10):6167-74.
 22. Nakata Y, **Kim TK**, Shetzline S, Gewirtz AM. Nucleic acid modulation of gene expression: approaches for nucleic acid therapeutics against cancer. *Crit Rev Eukaryot Gene Expr*. 2005; 15(2):163-82.
 23. Opalinska JB, Kalota A, Gifford LK, Lu P, Jen KY, Pradeepkumar PI, Barman J, **Kim TK**, Swider CR, Chattopadhyaya J, Gewirtz AM. Oxetane modified, conformationally constrained, antisense oligodeoxyribonucleotides function efficiently as gene silencing molecules, *Nucleic Acids Res*, 2004 Oct 28;32(19):5791-9.